APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gene Therapy on Cancer

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gene Therapy on Cancer Market Outlook and Growth Opportunities 2026

2 January 2026195 pages

Choose your research edition.

Industry ResearchGene Therapy on Cancer Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Therapy on Cancer Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Gene Therapy on Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Therapy on Cancer Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Therapy on Cancer Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Gene Therapy on Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gene Therapy on Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gene Therapy on Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gene Therapy on Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gene Therapy on Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gene Therapy on Cancer market include Novartis, Gilead Sciences, Amgen, Sibiono and Shanghai Sunway, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Gene Therapy on Cancer market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gene Therapy on Cancer and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gene Therapy on Cancer revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gene Therapy on Cancer market.

Gene Therapy on Cancer Segment by Company

Novartis

Gilead Sciences

Amgen

Sibiono

Shanghai Sunway

Gene Therapy on Cancer Segment by Type

Viral Gene Therapy

Non-viral Gene Therapy

Gene Therapy on Cancer Segment by Application

Hospital

Clinic

Other

Gene Therapy on Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Gene Therapy on Cancer status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gene Therapy on Cancer key companies, revenue, market share, and recent developments.

3. To split the Gene Therapy on Cancer breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gene Therapy on Cancer market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gene Therapy on Cancer significant trends, drivers, influence factors in global and regions.

6. To analyze Gene Therapy on Cancer competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy on Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy on Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy on Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene Therapy on Cancer industry.

Chapter 3: Detailed analysis of Gene Therapy on Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gene Therapy on Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gene Therapy on Cancer in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gene Therapy on Cancer Industry Trends Table 2. Gene Therapy on Cancer Industry Drivers Table 3. Gene Therapy on Cancer Industry Opportunities and Challenges Table 4. Gene Therapy on Cancer Industry Restraints Table 5. Global Gene Therapy on Cancer Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gene Therapy on Cancer Revenue Share by Company (2021-2026) Table 7. Global Gene Therapy on Cancer Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gene Therapy on Cancer Key Company Manufacturing Base & Headquarters Table 9. Global Gene Therapy on Cancer Company, Product Type & Application Table 10. Global Gene Therapy on Cancer Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gene Therapy on Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Viral Gene Therapy Table 15. Significant Companies of Non-viral Gene Therapy Table 16. Global Gene Therapy on Cancer Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Gene Therapy on Cancer Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Gene Therapy on Cancer Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Gene Therapy on Cancer Sales Value Share by Type (2021-2026) Table 20. Global Gene Therapy on Cancer Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Other Table 24. Global Gene Therapy on Cancer Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Gene Therapy on Cancer Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Gene Therapy on Cancer Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Gene Therapy on Cancer Sales Value Share by Application (2021-2026) Table 28. Global Gene Therapy on Cancer Sales Value Share by Application (2027-2032) Table 29. Global Gene Therapy on Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Gene Therapy on Cancer Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Gene Therapy on Cancer Sales Value Share by Region (2021-2026) Table 32. Global Gene Therapy on Cancer Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Gene Therapy on Cancer Sales Value Share by Region (2027-2032) Table 34. Global Gene Therapy on Cancer Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Gene Therapy on Cancer Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Gene Therapy on Cancer Sales Value Market Share by Country (2021-2026) Table 37. Global Gene Therapy on Cancer Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Gene Therapy on Cancer Sales Value Market Share by Country (2027-2032) Table 39. Novartis Company Information Table 40. Novartis Business Overview Table 41. Novartis Gene Therapy on Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Novartis Gene Therapy on Cancer Product Portfolio Table 43. Novartis Recent Development Table 44. Gilead Sciences Company Information Table 45. Gilead Sciences Business Overview Table 46. Gilead Sciences Gene Therapy on Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Gilead Sciences Gene Therapy on Cancer Product Portfolio Table 48. Gilead Sciences Recent Development Table 49. Amgen Company Information Table 50. Amgen Business Overview Table 51. Amgen Gene Therapy on Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Amgen Gene Therapy on Cancer Product Portfolio Table 53. Amgen Recent Development Table 54. Sibiono Company Information Table 55. Sibiono Business Overview Table 56. Sibiono Gene Therapy on Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Sibiono Gene Therapy on Cancer Product Portfolio Table 58. Sibiono Recent Development Table 59. Shanghai Sunway Company Information Table 60. Shanghai Sunway Business Overview Table 61. Shanghai Sunway Gene Therapy on Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Shanghai Sunway Gene Therapy on Cancer Product Portfolio Table 63. Shanghai Sunway Recent Development Table 64. Research Programs/Design for This Report Table 65. Authors List of This Report Table 66. Secondary Sources Table 67. Primary Sources List of Figures Figure 1. Gene Therapy on Cancer Product Image Figure 2. Global Gene Therapy on Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Therapy on Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Gene Therapy on Cancer Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Viral Gene Therapy Image Figure 8. Non-viral Gene Therapy Image Figure 9. Global Gene Therapy on Cancer Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Gene Therapy on Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Gene Therapy on Cancer Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Other Image Figure 15. Global Gene Therapy on Cancer Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Gene Therapy on Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Gene Therapy on Cancer Sales Value Share by Application (2021-2032) Figure 18. Global Gene Therapy on Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Gene Therapy on Cancer Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Gene Therapy on Cancer Sales Value (2021-2032) & (US$ Million) Figure 21. North America Gene Therapy on Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Gene Therapy on Cancer Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Gene Therapy on Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Gene Therapy on Cancer Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Gene Therapy on Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Gene Therapy on Cancer Sales Value (2021-2032) & (US$ Million) Figure 27. South America Gene Therapy on Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Gene Therapy on Cancer Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Gene Therapy on Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Gene Therapy on Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Therapy
  • Non-viral Gene Therapy
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Novartis
  • Gilead Sciences
  • Amgen
  • Sibiono
  • Shanghai Sunway

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gene Therapy on Cancer Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gene Therapy on Cancer Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gene Therapy on Cancer Market Dynamics
  1. 2.1 Gene Therapy on Cancer Industry Trends
  2. 2.2 Gene Therapy on Cancer Industry Drivers
  3. 2.3 Gene Therapy on Cancer Industry Opportunities and Challenges
  4. 2.4 Gene Therapy on Cancer Industry Restraints
3 Gene Therapy on Cancer Market by Company
  1. 3.1 Global Gene Therapy on Cancer Company Revenue Ranking in 2025
  2. 3.2 Global Gene Therapy on Cancer Revenue by Company (2021-2026)
  3. 3.3 Global Gene Therapy on Cancer Company Ranking (2024-2026)
  4. 3.4 Global Gene Therapy on Cancer Company Manufacturing Base and Headquarters
  5. 3.5 Global Gene Therapy on Cancer Company Product Type and Application
  6. 3.6 Global Gene Therapy on Cancer Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gene Therapy on Cancer Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gene Therapy on Cancer Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gene Therapy on Cancer Market by Type
  1. 4.1 Gene Therapy on Cancer Type Introduction
  2. 4.1.1 Viral Gene Therapy
  3. 4.1.2 Non-viral Gene Therapy
  4. 4.2 Global Gene Therapy on Cancer Sales Value by Type
  5. 4.2.1 Global Gene Therapy on Cancer Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gene Therapy on Cancer Sales Value by Type (2021-2032)
  7. 4.2.3 Global Gene Therapy on Cancer Sales Value Share by Type (2021-2032)
5 Gene Therapy on Cancer Market by Application
  1. 5.1 Gene Therapy on Cancer Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Gene Therapy on Cancer Sales Value by Application
  6. 5.2.1 Global Gene Therapy on Cancer Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gene Therapy on Cancer Sales Value by Application (2021-2032)
  8. 5.2.3 Global Gene Therapy on Cancer Sales Value Share by Application (2021-2032)
6 Gene Therapy on Cancer Regional Value Analysis
  1. 6.1 Global Gene Therapy on Cancer Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gene Therapy on Cancer Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gene Therapy on Cancer Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gene Therapy on Cancer Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gene Therapy on Cancer Sales Value (2021-2032)
  7. 6.3.2 North America Gene Therapy on Cancer Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gene Therapy on Cancer Sales Value (2021-2032)
  10. 6.4.2 Europe Gene Therapy on Cancer Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gene Therapy on Cancer Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gene Therapy on Cancer Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gene Therapy on Cancer Sales Value (2021-2032)
  16. 6.6.2 South America Gene Therapy on Cancer Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gene Therapy on Cancer Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gene Therapy on Cancer Sales Value Share by Country, 2025 VS 2032
7 Gene Therapy on Cancer Country-level Value Analysis
  1. 7.1 Global Gene Therapy on Cancer Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gene Therapy on Cancer Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gene Therapy on Cancer Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gene Therapy on Cancer Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gene Therapy on Cancer Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gene Therapy on Cancer Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gene Therapy on Cancer Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Gene Therapy on Cancer Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Gene Therapy on Cancer Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences Gene Therapy on Cancer Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences Gene Therapy on Cancer Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Gene Therapy on Cancer Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Gene Therapy on Cancer Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Sibiono
  20. 8.4.1 Sibiono Company Information
  21. 8.4.2 Sibiono Business Overview
  22. 8.4.3 Sibiono Gene Therapy on Cancer Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sibiono Gene Therapy on Cancer Product Portfolio
  24. 8.4.5 Sibiono Recent Developments
  25. 8.5 Shanghai Sunway
  26. 8.5.1 Shanghai Sunway Company Information
  27. 8.5.2 Shanghai Sunway Business Overview
  28. 8.5.3 Shanghai Sunway Gene Therapy on Cancer Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shanghai Sunway Gene Therapy on Cancer Product Portfolio
  30. 8.5.5 Shanghai Sunway Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst